MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

Abstract

Purpose: The aim of this study was to identify noninvasive pharmacodynamic biomarkers of FGFR3-targeted therapies in bladder cancer to facilitate the clinical development of experimental agent targeting FGFR3.Experimental Design: Potential soluble pharmacodynamic biomarkers of FGFR3 were identified using a combination of transcriptional profiling and biochemical analyses in preclinical models. Two matrix metalloproteinases (MMP), MMP-1 and MMP-10, were selected for further studies in human bladder cancer xenograft models treated with a specific anti-FGFR3 monoclonal antibody, R3Mab. Serum and urinary levels of MMP-1 and MMP-10 were determined in healthy donors and patients with bladder cancer. The modulation of MMP-1 and MMP-10 by R3Mab in patients with bladder cancer was further evaluated in a phase I dose-escalation study.Results: MMP-1 and MMP-10 mRNA and protein were downmodulated by FGFR3 shRNA and R3Mab in bladder cancer cell lines. FGFR3 signaling promoted the expression and secretion of MMP-1 and pro-MMP-10 in a MEK-dependent fashion. In bladder cancer xenograft models, R3Mab substantially blocked tumor progression and reduced the protein levels of human MMP-1 and pro-MMP-10 in tumor tissues as well as in mouse serum. Furthermore, both MMP-1 and pro-MMP-10 were elevated in the urine of patients with advanced bladder cancer. In a phase I dose-escalation trial, R3Mab administration resulted in an acute reduction of urinary MMP-1 and pro-MMP-10 levels in patients with bladder cancer.Conclusion: These findings reveal a critical role of FGFR3 in regulating MMP-1 and pro-MMP-10 expression and secretion, and identify urinary MMP-1 and pro-MMP-10 as potential pharmacodynamic biomarkers for R3Mab in patients with bladder cancer. Clin Cancer Res; 20(24); 6324-35. Ó2014 AACR.

Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis

“…In the serum of 10 healthy control subjects, the mean concentration of MMP-10, 986 pg/mL, was consistent with published data [58,59] (Fig. 6A).…”

Matrix metalloproteinases as potential fecal biomarkers for ulcerative colitis – a function beyond their proteolytic activity

“…36 It has also been found to be a key marker of epithelial mesenchymal transition during progression of UC to colon cancer. 37 MMP1 has already been established as a blood biomarker for chronic progressive fibrotic lung disease 38 and as a urinary biomarker for bladder cancer, 39 supporting its stability as a secretory protein in different human body fluids; hence, we propose it as a potential candidate for fecal biomarker of UC.…”

“…In bladder cancer, it has been shown as a urinary pharmacodynamic biomarker. 39 Its efficiency as a cerebrospinal fluid has been demonstrated in Alzheimer's disease. 74 Thus, MMP10 may be worth considering as a fecal biomarker.…”

FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression

“…Proteolytic degradation of the extracellular matrix (ECM) and the basement membranes surrounding the primary tumor by the matrix metalloproteinase (MMP) is a critical step for tumor angiogenesis, invasion, and metastasis (9). The MMPs have served as potential prognostic markers and therapeutic targets in cancer (10). Previously, we established an isogenic lung cancer metastasis cell model and discovered several metastasis-related gene (11)(12)(13)(14)(15)(16)(17)(18).…”